Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer - Annals of Oncology
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer - Annals of Oncology
MONALEESA Analysis - 2021 SABCS Symposium - Module - SABCS 2021 - Oncology - Clinical Care Options
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer - Annals of Oncology
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
Safety and impact of dose reductions on efficacy in the randomised MONALEESA -2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer | NEJM
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial - The Breast
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
Dr Sunil Verma on Twitter: "Monaleesa 7 results by @DrDebuTripathy - first line Ribociclib in pre/peri-menopausal HR+ve MBC. Improved PFS (HR 0.55) #SABCS17 https://t.co/rOYQSEEH7C" / Twitter
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
Efficacy of KISQALI® (ribociclib) + AI in Postmenopausal | HCP
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
MONALEESA-3 OS Update - Capsule Summary Slidesets - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
BOOG Study Center - Studie
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast
Novartis Kisqali® (ribociclib, LEE011) receives FDA approval
MONALEESA-2: Overall Survival Benefit Demonstrated in HR+ Advanced Breast Cancer with CDK 4/6 Inhibitor - The Medical Xchange
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study - Clinical Breast Cancer
Frontiers | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
